Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 99.18 USD -0.68% Market Closed
Market Cap: 250.9B USD
Have any thoughts about
Merck & Co Inc?
Write Note

Net Margin
Merck & Co Inc

19.2%
Current
18%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
19.2%
=
Net Income
12.1B
/
Revenue
63.2B

Net Margin Across Competitors

Country US
Market Cap 251.1B USD
Net Margin
19%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
Country US
Market Cap 145.4B USD
Net Margin
7%
No Stocks Found

Merck & Co Inc
Glance View

Market Cap
251.1B USD
Industry
Pharmaceuticals

Merck & Co., Inc., a global leader in the pharmaceutical industry, has been on a transformative journey that reflects its commitment to innovation and improving health outcomes around the world. Founded in 1891, the company has grown into a powerhouse known for its diverse product portfolio, which includes groundbreaking vaccines, oncology therapies, and treatments for chronic diseases. With a rich history of fostering research and development, Merck invests heavily in scientific advancements, positioning itself at the forefront of medical breakthroughs. This dedication has led to the successful launch of key products, such as the human papillomavirus (HPV) vaccine Gardasil and the cancer immunotherapy Keytruda, which has gained significant traction and revenue, making it one of the top-selling drugs globally. As an investor, understanding Merck's strategic direction is crucial. The company is not only focused on maintaining its legacy in pharmaceuticals but also on expanding its presence in biopharma through collaborations and acquisitions, enhancing its pipeline of potential therapies. With a robust dividend history, Merck has demonstrated its commitment to returning value to shareholders, signifying financial stability and confidence in ongoing business fundamentals. Furthermore, as the global demand for innovative health solutions accelerates, Merck's proactive approach to addressing emerging health challenges positions it for sustainable growth. For investors, the combination of Merck’s rich heritage, innovative spirit, and sound financial practices creates an appealing narrative that carries potential for long-term returns.

MRK Intrinsic Value
136.99 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
19.2%
=
Net Income
12.1B
/
Revenue
63.2B
What is the Net Margin of Merck & Co Inc?

Based on Merck & Co Inc's most recent financial statements, the company has Net Margin of 19.2%.